CSHL has several researchers working on pancreatic cancer. David Tuveson, M.D., Ph.D., Professor, directs the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL.
Lustgarten Foundation Pancreatic Cancer Research Laboratory
The Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, led by David Tuveson, M.D., Ph.D. is centered on early detection, drug development and drug delivery. The research will focus initially on three key aspects of pancreatic cancer:
- Developing ways to detect pancreatic cancer early—The presence of cancer in the pancreas causes changes in a person’s system that may be detected in bodily fluids, such as blood or urine. These changes will be identified so that they can be used to routinely test patients for the presence of pancreatic cancer in its earliest stages.
- Identifying new targets for drug development—New pathways will be explored that could potentially uncover new therapeutic approaches for drug development to kill and eliminate pancreatic cancers.
- Using more effective approaches to deliver drugs directly to pancreatic cancers—Existing research shows that pancreatic tumors are difficult to penetrate with chemotherapy, so new methods will be developed to ensure that the chemotherapy reaches the tumor for more effective treatment.
In addition to directing the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, Dr. Tuveson is also the Director of Research for the Lustgarten Foundation. In this capacity, he oversees the development of fundable research and works with the Foundation’s Pancreatic Cancer Research Consortium of six, world-renowned medical institutions to identify, prioritize and develop targeted research aimed at ultimately finding a cure for this deadly disease.
Pancreatic cancer hijacks a brain-building protein
February 14, 2024
CSHL researchers have found that EN-1, a protein involved in neurodevelopment, can help pancreatic cancer spread throughout the body.
How diet may impact cancer and possible treatments
February 1, 2024
Researchers at the CSHL Cancer Center study the links between disease and nutrition in hopes of uncovering new treatment and prevention strategies.
Can we crack this cancer’s immune response?
November 29, 2023
CSHL research brings scientists closer to understanding how pancreatic cancer interacts with our immune system and why immunotherapy hasn’t worked.
Growing human organs in the lab
August 3, 2023
It’s not something out of science-fiction. It’s a real biomedical breakthrough. This video, with organoid expert Dr. James Wells, shows how it works.
The latest weapon against cancer is … a keto diet?
June 12, 2023
CSHL researchers find that pairing keto with a prescription steroid may offer a potential treatment for pancreatic and colorectal cancer.
This killer protein causes pancreatic cancer
April 26, 2023
CSHL researchers have found that high levels of a protein called SRSF1 can cause pancreatitis and jumpstart tumor development.
David Tuveson wins 2022 Luminary Award
November 17, 2022
The award, presented on World Pancreatic Cancer Day, honors Tuveson for his efforts to find a cure and improve patients’ lives.
Welcome to Biology + Beyond
November 14, 2022
CSHL President and CEO Bruce Stillman introduces a special issue of Nautilus magazine now online, featuring the Lab’s latest groundbreaking research
Targeting cancer’s Achilles heel
November 4, 2022
Biden’s Cancer Moonshot aims to cut annual deaths in half. CSHL scientists have the goal in their sights.
David Tuveson elected to National Academy of Medicine
October 17, 2022
Tuveson was recognized for his pioneering cancer organoid research that led to the development of the first mouse models for pancreatic cancer.